Literature DB >> 17945216

Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole.

Sérgio Caldas1, Fabiane M Santos, Marta de Lana, Lívia F Diniz, George L L Machado-Coelho, Vanja M Veloso, Maria T Bahia.   

Abstract

We analyzed the influence of Trypanosoma cruzi maintenance in different hosts (dog and mouse) on its susceptibility to benznidazole treatment. Five T. cruzi stocks were isolated from dogs inoculated with Be-62 or Be-78 strain (both sensitive to benznidazole) 2-10 years ago, and the benznidazole sensitivity was then determined using the mouse as experimental model. The different T. cruzi stocks obtained from long-term infected dogs showed 50-90% drug resistance right after isolation. However, maintenance of these T. cruzi stocks in mice, by successive blood passages (2.5 years), led to either a decrease or stability of the drug resistance pattern and an increase in parasite virulence. We also demonstrated the effectiveness of the induction of parasitemia reactivation by cyclophosphamide immunosuppression in the evaluation of the response to the specific drug treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17945216     DOI: 10.1016/j.exppara.2007.08.016

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  15 in total

1.  Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.

Authors:  Frederick S Buckner; Maria Terezinha Bahia; Praveen Kumar Suryadevara; Karen L White; David M Shackleford; Naveen Kumar Chennamaneni; Matthew A Hulverson; Joy U Laydbak; Eric Chatelain; Ivan Scandale; Christophe L M J Verlinde; Susan A Charman; Galina I Lepesheva; Michael H Gelb
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

2.  Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.

Authors:  Maria T Bahia; Alvaro F S Nascimento; Ana Lia Mazzeti; Luiz F Marques; Karolina R Gonçalves; Ludmilla W R Mota; Lívia de F Diniz; Ivo S Caldas; André Talvani; David M Shackleford; Maria Koltun; Jessica Saunders; Karen L White; Ivan Scandale; Susan A Charman; Eric Chatelain
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Amlodipine Increases the Therapeutic Potential of Ravuconazole upon Trypanosoma cruzi Infection.

Authors:  Yara Almeida Machado; Maria Terezinha Bahia; Ivo Santana Caldas; Ana Lia Mazzeti; Rômulo Dias Novaes; Breno Raimundo Vilas Boas; Lorena Júnia de Souza Santos; Olindo Assis Martins-Filho; Marcos José Marques; Lívia de Figueiredo Diniz
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

4.  Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.

Authors:  Ana Paula Gruendling; Miyoko Massago; Ana Paula M Teston; Wuelton M Monteiro; Edilson N Kaneshima; Silvana M Araújo; Mônica L Gomes; Maria das Graças V Barbosa; Max Jean O Toledo
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

5.  Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.

Authors:  Ivo Santana Caldas; André Talvani; Sérgio Caldas; Cláudia Martins Carneiro; Marta de Lana; Paulo Marcos da Matta Guedes; Maria Terezinha Bahia
Journal:  Parasitol Res       Date:  2008-05-04       Impact factor: 2.289

6.  Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.

Authors:  Shilpi Khare; Xianzhong Liu; Monique Stinson; Ianne Rivera; Todd Groessl; Tove Tuntland; Vince Yeh; Ben Wen; Valentina Molteni; Richard Glynne; Frantisek Supek
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

7.  Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease.

Authors:  Rômulo Dias Novaes; Marcus Vinicius Pessoa Sartini; João Paulo Ferreira Rodrigues; Reggiani Vilela Gonçalves; Eliziária Cardoso Santos; Raquel Lopes Martins Souza; Ivo Santana Caldas
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

8.  New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Authors:  Juan M Bustamante; Julie M Craft; Byron D Crowe; Sarah A Ketchie; Rick L Tarleton
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

9.  Fexinidazole: a potential new drug candidate for Chagas disease.

Authors:  Maria Terezinha Bahia; Isabel Mayer de Andrade; Tassiane Assíria Fontes Martins; Álvaro Fernando da Silva do Nascimento; Lívia de Figueiredo Diniz; Ivo Santana Caldas; André Talvani; Bernadette Bourdin Trunz; Els Torreele; Isabela Ribeiro
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

10.  Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain.

Authors:  Kátia da Silva Fonseca; Luísa Perin; Nívia Carolina Nogueira de Paiva; Beatriz Cristiane da Silva; Thays Helena Chaves Duarte; Flávia de Souza Marques; Guilherme de Paula Costa; Israel Molina; Rodrigo Correa-Oliveira; Paula Melo de Abreu Vieira; Cláudia Martins Carneiro
Journal:  Pathogens       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.